{"title":"致幻剂研究人员对致幻剂的亲身体验,他们与致幻剂观点的联系,以及对位置性的反思。","authors":"Jussi Jylkkä, Aila Mustamo","doi":"10.1007/s00213-025-06871-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Anecdotal evidence suggests that psychedelic researchers often have personal experiences with psychedelic substances. While such experiences may benefit research, concerns have been raised about potential biases and \"excessive enthusiasm.\" However, the prevalence of personal experiences, their perceived relevance, and their association with opinions about psychedelics remain underexplored.</p><p><strong>Objectives: </strong>This study aimed to investigate how common personal psychedelic experiences are among psychedelic researchers, their perceived relevance to research, and whether personal use is associated with opinions about psychedelics.</p><p><strong>Methods: </strong>Participants (N = 111) conducting psychedelic research in academic settings were recruited. Data were collected on personal experiences, their perceived relevance, and opinions about psychedelics. Regression analyses examined associations between personal use and opinions.</p><p><strong>Results: </strong>Most respondents (85%) reported personal experiences with classic psychedelics. On average, they saw personal experience as beneficial for research, but also as potential source of bias. They acknowledged the importance of self-reflection and the need to disclose personal experiences, but found disclosure challenging in practice. Personal use predicted more positive opinions about psychedelics' potential to improve well-being, transform society, address the ecological crisis, and answer spiritual questions (regression βs = 0.3 - 0.5, ps < 0.01).</p><p><strong>Conclusions: </strong>The findings highlight the prevalence of personal psychedelic experiences among this sample of researchers and their influence on research interests and opinions. The results underscore the need for open discussion and reflection. Future studies should explore whether the observed associations reflect causal relationships or potential biases.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychedelic researchers' own experiences of psychedelic substances, their link to opinions of psychedelics, and reflections on positionality.\",\"authors\":\"Jussi Jylkkä, Aila Mustamo\",\"doi\":\"10.1007/s00213-025-06871-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>Anecdotal evidence suggests that psychedelic researchers often have personal experiences with psychedelic substances. While such experiences may benefit research, concerns have been raised about potential biases and \\\"excessive enthusiasm.\\\" However, the prevalence of personal experiences, their perceived relevance, and their association with opinions about psychedelics remain underexplored.</p><p><strong>Objectives: </strong>This study aimed to investigate how common personal psychedelic experiences are among psychedelic researchers, their perceived relevance to research, and whether personal use is associated with opinions about psychedelics.</p><p><strong>Methods: </strong>Participants (N = 111) conducting psychedelic research in academic settings were recruited. Data were collected on personal experiences, their perceived relevance, and opinions about psychedelics. Regression analyses examined associations between personal use and opinions.</p><p><strong>Results: </strong>Most respondents (85%) reported personal experiences with classic psychedelics. On average, they saw personal experience as beneficial for research, but also as potential source of bias. They acknowledged the importance of self-reflection and the need to disclose personal experiences, but found disclosure challenging in practice. Personal use predicted more positive opinions about psychedelics' potential to improve well-being, transform society, address the ecological crisis, and answer spiritual questions (regression βs = 0.3 - 0.5, ps < 0.01).</p><p><strong>Conclusions: </strong>The findings highlight the prevalence of personal psychedelic experiences among this sample of researchers and their influence on research interests and opinions. The results underscore the need for open discussion and reflection. Future studies should explore whether the observed associations reflect causal relationships or potential biases.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06871-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06871-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Psychedelic researchers' own experiences of psychedelic substances, their link to opinions of psychedelics, and reflections on positionality.
Rationale: Anecdotal evidence suggests that psychedelic researchers often have personal experiences with psychedelic substances. While such experiences may benefit research, concerns have been raised about potential biases and "excessive enthusiasm." However, the prevalence of personal experiences, their perceived relevance, and their association with opinions about psychedelics remain underexplored.
Objectives: This study aimed to investigate how common personal psychedelic experiences are among psychedelic researchers, their perceived relevance to research, and whether personal use is associated with opinions about psychedelics.
Methods: Participants (N = 111) conducting psychedelic research in academic settings were recruited. Data were collected on personal experiences, their perceived relevance, and opinions about psychedelics. Regression analyses examined associations between personal use and opinions.
Results: Most respondents (85%) reported personal experiences with classic psychedelics. On average, they saw personal experience as beneficial for research, but also as potential source of bias. They acknowledged the importance of self-reflection and the need to disclose personal experiences, but found disclosure challenging in practice. Personal use predicted more positive opinions about psychedelics' potential to improve well-being, transform society, address the ecological crisis, and answer spiritual questions (regression βs = 0.3 - 0.5, ps < 0.01).
Conclusions: The findings highlight the prevalence of personal psychedelic experiences among this sample of researchers and their influence on research interests and opinions. The results underscore the need for open discussion and reflection. Future studies should explore whether the observed associations reflect causal relationships or potential biases.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.